Check Cap (NASDAQ:CHEK) Earning Somewhat Critical News Coverage, Accern Reports

Media coverage about Check Cap (NASDAQ:CHEK) has been trending somewhat negative recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Check Cap earned a daily sentiment score of -0.06 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 46.8064426436494 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

A number of research analysts have weighed in on CHEK shares. Zacks Investment Research raised Check Cap from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a report on Monday, January 15th. HC Wainwright began coverage on Check Cap in a research report on Tuesday, March 13th. They issued a “buy” rating and a $6.00 price target for the company.

Shares of CHEK opened at $0.51 on Tuesday. The stock has a market capitalization of $9.98, a price-to-earnings ratio of -0.84 and a beta of 0.07. Check Cap has a 52 week low of $0.47 and a 52 week high of $2.38.

TRADEMARK VIOLATION NOTICE: “Check Cap (NASDAQ:CHEK) Earning Somewhat Critical News Coverage, Accern Reports” was first reported by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://baseballnewssource.com/2018/04/03/somewhat-critical-press-coverage-somewhat-unlikely-to-impact-check-cap-chek-stock-price/2010336.html.

About Check Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Insider Buying and Selling by Quarter for Check Cap (NASDAQ:CHEK)

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Didi Gregorius Starts Season Hot at the Plate
Didi Gregorius Starts Season Hot at the Plate
Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox


Leave a Reply

 
© 2006-2018 BBNS.